Table 3.
Therapeutic area by utility of molecular imaging
| Therapeutic area | Utility of molecular imaging | |||||
|---|---|---|---|---|---|---|
| Efficacy | POC/RO | POC/non-RO | PK | Total | p value | |
| Oncology | 90 (84.9) | 1 (0.9) | 4 (3.8) | 11 (10.4) | 106 (100.0) | |
| CNS | 22 (27.2) | 49 (60.5) | 7 (8.6) | 3 (3.7) | 81 (100.0) | |
| Cardiovascular | 21 (91.3) | 0 (0.0) | 2 (8.7) | 0 (0.0) | 23 (100.0) | |
| Gastrointestinal | 3 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (100.0) | |
| Antibiotics | 2 (66.7) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 3 (100.0) | |
| Others | 3 (50.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) | 6 (100.0) | |
| Total | 141 (63.5) | 50 (22.5) | 16 (7.2) | 15 (6.8) | 222 (100.0) | < 0.0001 |
Frequency (row percentage) is shown. The total number was 222 because multiple choice was allowed in a single paper
POC/RO, proof-of-concept based on receptor occupancy; POC/non-RO, proof-of-concept other than through receptor occupancy; PK, pharmacokinetics; CNS, central nervous system